Curat Global LLC Makes New $32,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Curat Global LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 50 shares of the biopharmaceutical company’s stock, valued at approximately $32,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Capital International Investors lifted its holdings in Regeneron Pharmaceuticals by 41.6% in the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock worth $3,373,859,000 after purchasing an additional 1,390,534 shares during the last quarter. Norges Bank acquired a new position in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $802,036,000. GAMMA Investing LLC raised its position in shares of Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock valued at $517,291,000 after purchasing an additional 814,713 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Regeneron Pharmaceuticals by 63.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock worth $1,485,527,000 after buying an additional 810,144 shares during the last quarter. Finally, Amundi lifted its stake in shares of Regeneron Pharmaceuticals by 45.8% in the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock worth $1,138,074,000 after buying an additional 487,489 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $493.22 on Friday. The business’s fifty day moving average is $569.75 and its two-hundred day moving average is $657.70. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The firm has a market cap of $53.25 billion, a P/E ratio of 12.88, a P/E/G ratio of 2.34 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s quarterly revenue was down 3.7% on a year-over-year basis. During the same quarter last year, the company earned $9.55 EPS. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.71%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.96%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Cantor Fitzgerald started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $695.00 price target on the stock. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 1st. BMO Capital Markets cut their target price on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an “outperform” rating for the company in a research note on Monday, June 2nd. Royal Bank of Canada downgraded shares of Regeneron Pharmaceuticals from a “moderate buy” rating to a “hold” rating and set a $662.00 price target for the company. in a report on Friday, May 30th. Finally, UBS Group dropped their price objective on shares of Regeneron Pharmaceuticals from $633.00 to $560.00 and set a “neutral” rating on the stock in a report on Thursday. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $844.48.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.